Jonsson Comprehensive Cancer Center
This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.
Glioblastoma
Computed Tomography
Fludeoxyglucose F-18
Positron Emission Tomography
NA
PRIMARY OBJECTIVES: I. To assess very early response to therapy in glioblastoma patients using 18F-FDG PET/CT. II. Evaluate very early changes in FDG uptake within 48 hours of start of therapy and correlate them with objective response parameters such as Response Assessment in Neuro-Oncology (RANO) and survival. OUTLINE: Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 50 participants |
| Masking : | NONE |
| Primary Purpose : | DIAGNOSTIC |
| Official Title : | Very Early Response Monitoring in Patients With Glioblastoma Undergoing Therapy Using FDG PET/CT |
| Actual Study Start Date : | 2015-08-25 |
| Estimated Primary Completion Date : | 2025-08-25 |
| Estimated Study Completion Date : | 2026-08-25 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years to 99 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States, 90095